Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528404 | 1.00 | — | — | |
| SCHEMBL25769149 | 1.00 | CARM1 (0.33) | CARM1PRMT6PRMT8MGLL | |
| SCHEMBL1092361 | 1.00 | — | — | |
| Bromide SCHEMBL7065182 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL28297139 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL1027109 | 0.97 | CARM1 (0.32) | CARM1PRMT6PRMT8 | |
| Hydrochloric Acid SCHEMBL28745686 | 0.97 | CARM1 (0.32) | CARM1PRMT6PRMT8 | |
| SCHEMBL528887 | 0.96 | — | — | |
| SCHEMBL15388363 | 0.96 | — | — | |
| Bromide SCHEMBL4361146 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015851-A1 | TREATMENT OF CELL PROLIFERATION-ASSOCIATED CONDITIONS USING A COMBINATION OF A CLB-B INHIBITOR AND AN ADDITIONAL THERAPEUTIC AGENT | HOTSPOT THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2021067791-A1 | OXALAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020264398-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-2678035-B1 | PHENALENE-1-ONE DERIVATIVES, METHOD FOR PRODUCING SAME AND USE THEREOF | TRIOPTOTEC GMBH (DE) | 2019-04-10 | — | — | EP | disclosed |
| US-20040242888-A1 | Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1460061-A1 | PROCESS FOR PRODUCING 1-ALKOXYCARBONYL NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242888-A1 | Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative | DAO, DDO, ODC1 | CARM1 107/4885PRMT6 262/4885PRMT8 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.